CA1076026A - Methode pour separer l'albumine dans les derives du sang - Google Patents

Methode pour separer l'albumine dans les derives du sang

Info

Publication number: CA1076026A
Authority: CA; Canada
Prior art keywords: albumin; buffer; ionic strength; exchanger; separation
Prior art date: 1976-10-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA262,876A

Other languages

English (en)

Inventor

Lars-Olof E. Lindquist

Jan H. Berglof

John M. Curling

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Cytiva Sweden AB

Original Assignee

Pharmacia Fine Chemicals AB

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1976-10-06

Filing date

1976-10-06

Publication date

1980-04-22

1976-10-06 Application filed by Pharmacia Fine Chemicals AB filed Critical Pharmacia Fine Chemicals AB

1976-10-06 Priority to CA262,876A priority Critical patent/CA1076026A/fr

1980-04-22 Application granted granted Critical

1980-04-22 Publication of CA1076026A publication Critical patent/CA1076026A/fr

Status Expired legal-status Critical Current

Links

102000009027 Albumins Human genes 0.000 title claims abstract description 58
108010088751 Albumins Proteins 0.000 title claims abstract description 58
238000000034 method Methods 0.000 title claims abstract description 31
239000010836 blood and blood product Substances 0.000 title description 4
229940125691 blood product Drugs 0.000 title description 4
239000000872 buffer Substances 0.000 claims abstract description 29
150000001450 anions Chemical class 0.000 claims abstract description 24
150000001768 cations Chemical class 0.000 claims abstract description 21
239000012062 aqueous buffer Substances 0.000 claims abstract description 10
108010039209 Blood Coagulation Factors Proteins 0.000 claims abstract description 3
102000015081 Blood Coagulation Factors Human genes 0.000 claims abstract description 3
239000003114 blood coagulation factor Substances 0.000 claims abstract description 3
238000005342 ion exchange Methods 0.000 claims description 13
238000005406 washing Methods 0.000 claims description 11
238000010828 elution Methods 0.000 claims description 6
229920000620 organic polymer Polymers 0.000 claims description 3
239000008351 acetate buffer Substances 0.000 claims description 2
239000007979 citrate buffer Substances 0.000 claims description 2
238000004440 column chromatography Methods 0.000 claims 1
238000000926 separation method Methods 0.000 abstract description 21
238000013375 chromatographic separation Methods 0.000 abstract description 5
239000000243 solution Substances 0.000 description 16
210000002381 plasma Anatomy 0.000 description 12
229920005654 Sephadex Polymers 0.000 description 11
150000002500 ions Chemical class 0.000 description 11
BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 11
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
239000012507 Sephadex™ Substances 0.000 description 7
239000012847 fine chemical Substances 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
238000011282 treatment Methods 0.000 description 6
229920000936 Agarose Polymers 0.000 description 5
229920002307 Dextran Polymers 0.000 description 5
239000000047 product Substances 0.000 description 5
239000007858 starting material Substances 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
-1 diethyl-(2-hydroxypropyl)-aminoethyl Chemical group 0.000 description 4
239000012153 distilled water Substances 0.000 description 4
239000012467 final product Substances 0.000 description 4
239000011159 matrix material Substances 0.000 description 4
239000002244 precipitate Substances 0.000 description 4
235000018102 proteins Nutrition 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
239000007974 sodium acetate buffer Substances 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
108010017384 Blood Proteins Proteins 0.000 description 3
102000004506 Blood Proteins Human genes 0.000 description 3
229920002271 DEAE-Sepharose Polymers 0.000 description 3
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
238000005349 anion exchange Methods 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
238000005194 fractionation Methods 0.000 description 3
238000002955 isolation Methods 0.000 description 3
229920000642 polymer Polymers 0.000 description 3
239000001632 sodium acetate Substances 0.000 description 3
235000017281 sodium acetate Nutrition 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
108010049003 Fibrinogen Proteins 0.000 description 2
102000008946 Fibrinogen Human genes 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
238000005341 cation exchange Methods 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
239000000499 gel Substances 0.000 description 2
238000002523 gelfiltration Methods 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
230000003169 placental effect Effects 0.000 description 2
239000003058 plasma substitute Substances 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
229940057838 polyethylene glycol 4000 Drugs 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
238000000746 purification Methods 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
238000011146 sterile filtration Methods 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
230000008961 swelling Effects 0.000 description 2
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 1
241000237074 Centris Species 0.000 description 1
102100022641 Coagulation factor IX Human genes 0.000 description 1
102100023804 Coagulation factor VII Human genes 0.000 description 1
102100029117 Coagulation factor X Human genes 0.000 description 1
238000000665 Cohn process Methods 0.000 description 1
108010076282 Factor IX Proteins 0.000 description 1
108010023321 Factor VII Proteins 0.000 description 1
108010054218 Factor VIII Proteins 0.000 description 1
102000001690 Factor VIII Human genes 0.000 description 1
108010014173 Factor X Proteins 0.000 description 1
102000006395 Globulins Human genes 0.000 description 1
108010044091 Globulins Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
238000003527 Peterson olefination reaction Methods 0.000 description 1
108010094028 Prothrombin Proteins 0.000 description 1
102100027378 Prothrombin Human genes 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical group OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
241000700605 Viruses Species 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
125000000217 alkyl group Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
125000004103 aminoalkyl group Chemical group 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
238000011033 desalting Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
125000004985 dialkyl amino alkyl group Chemical group 0.000 description 1
125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
229940012952 fibrinogen Drugs 0.000 description 1
239000000727 fraction Substances 0.000 description 1
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
239000011544 gradient gel Substances 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
230000000951 immunodiffusion Effects 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
239000000463 material Substances 0.000 description 1
238000005374 membrane filtration Methods 0.000 description 1
239000000203 mixture Substances 0.000 description 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
235000004252 protein component Nutrition 0.000 description 1
239000002994 raw material Substances 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000001172 regenerating effect Effects 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
229960005480 sodium caprylate Drugs 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
BYKRNSHANADUFY-UHFFFAOYSA-M sodium octanoate Chemical compound [Na+].CCCCCCCC([O-])=O BYKRNSHANADUFY-UHFFFAOYSA-M 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
229910021653 sulphate ion Inorganic materials 0.000 description 1
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
235000019263 trisodium citrate Nutrition 0.000 description 1
229940038773 trisodium citrate Drugs 0.000 description 1

Landscapes

Peptides Or Proteins (AREA)

CA262,876A 1976-10-06 1976-10-06 Methode pour separer l'albumine dans les derives du sang Expired CA1076026A (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA262,876A CA1076026A (fr)	1976-10-06	1976-10-06	Methode pour separer l'albumine dans les derives du sang

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA262,876A CA1076026A (fr)	1976-10-06	1976-10-06	Methode pour separer l'albumine dans les derives du sang

Publications (1)

Publication Number	Publication Date
CA1076026A true CA1076026A (fr)	1980-04-22

Family

ID=4107011

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA262,876A Expired CA1076026A (fr)	1976-10-06	1976-10-06	Methode pour separer l'albumine dans les derives du sang

Country Status (1)

Country	Link
CA (1)	CA1076026A (fr)

1976
- 1976-10-06 CA CA262,876A patent/CA1076026A/fr not_active Expired

Legal Events

Date	Code	Title	Description
1997-04-22	MKEX	Expiry

Publication	Publication Date	Title
US4086222A (en)	1978-04-25	Method of isolating albumin from blood products
US5252709A (en)	1993-10-12	Chromatographic separation of plasma proteins
US5177194A (en)	1993-01-05	Process for purifying immune serum globulins
US3920625A (en)	1975-11-18	Isolation of coagulation factors from biological material using cross linked sulfated, sulfonated carbohydrates
JP3018412B2 (ja)	2000-03-13	血漿蛋白の分画方法
JP4445202B2 (ja)	2010-04-07	治療的使用のためのヒト免疫グロブリン濃縮物の調製方法
US5259951A (en)	1993-11-09	Process for the purification of factor VIII and factor VIII obtained by said process
IE61756B1 (en)	1994-11-30	Purification and activation of proteins from insoluble inclusion bodies
CZ287186B6 (en)	2000-10-11	Process for preparing concentrate free of aggregation of immunoglobulins G
PL168353B1 (pl)	1996-02-29	Sposób wytwarzania zatezonego, standaryzowanego ludzkiego c z y n n i k a von Willebranda o wysokiej czystosci PL PL PL PL PL PL PL
JPH08176198A (ja)	1996-07-09	新規なクロマトグラフイー分離条件を用いるα−１プロテイナーゼ阻害剤の精製
JPS62108821A (ja)	1987-05-20	アルフア−１−プロテイナ−ゼ阻害剤の製造方法
US5250662A (en)	1993-10-05	Albumin purification
JPH0768275B2 (ja)	1995-07-26	ウイルスの不活性化および活性蛋白質の精製
CA2085953C (fr)	2002-02-19	Preparation d'antithrombine iii humaine
US4075197A (en)	1978-02-21	Serum albumin production
US7041798B1 (en)	2006-05-09	Method for the chromatographic fractionation of plasma or serum, preparations, so obtained, and their use
US4097473A (en)	1978-06-27	Production of serum albumin
US5677424A (en)	1997-10-14	Method for purifying an aqueous solution of raw albumin
EP0422769B1 (fr)	1997-04-09	Purification d'albumine
JPH11500910A (ja)	1999-01-26	生物源からｉｘ因子を調製する方法
CA1076026A (fr)	1980-04-22	Methode pour separer l'albumine dans les derives du sang
US4610815A (en)	1986-09-09	Process for producing and obtaining anaphylatoxin- and cocytotaxin-containing leucotaxine preparations and of anaphylatoxin and cocytotaxin proteins in molecularly homogeneous, biologically active form
JPH09286797A (ja)	1997-11-04	ヘパリンコファクターｉｉ及びその精製方法
Leibl et al.	1996	Method for the isolation of biologically active monomeric immunoglobulin A from a plasma fraction